The Clinical Advisor

The Clinical Advisor is a monthly publication designed for nurse practitioners and physician assistants working in primary care. Its goal is to provide these healthcare professionals with current insights on diagnosing, treating, managing, and preventing common conditions encountered in a typical office environment.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#278109

United States

#91375

Health/Health

#1920

Traffic sources

Monthly visitors

Articles

Icotrokinra Improves Skin Clearance in Scalp, Genital Psoriasis

2 days ago | clinicaladvisor.com | Jaymin Kang

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study. Icotrokinra is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of plaque psoriasis and other IL-23 mediated diseases.
Law Enforcement Efforts Increase Fatal Opioid Overdose in SF Communities

3 days ago | clinicaladvisor.com | Hibah Khaja

Law enforcement efforts to disrupt illegal drug markets may unintentionally raise the risk for fatal opioid overdoses in the surrounding community, according to a cross-sectional study published in JAMA Network Open. Opioid-involved overdose mortality continues to be a major public health crisis in the US, driven largely by the presence of fentanyl and its analogs in an unregulated drug supply.
Diagnostics Expand Prognostic Evaluation in Athletes With Ventricular Arrhythmias

3 days ago | clinicaladvisor.com | Ron Goldberg

Prognostic assessment of athletes with complex ventricular arrhythmias (VAs) can be improved with a diagnostic evaluation incorporating imaging results with electrocardiogram (ECG) and clinical findings with careful use of invasive electrophysiology studies (EPSs), according to study results presented at Heart Rhythm 2025, held from April 24 to 27, 2025, in San Diego, California.
Cenobamate for Drug-Resistant Epilepsy May Reduce Seizures, Improve Retention

1 week ago | clinicaladvisor.com | Hibah Khaja

Patients with drug-resistant epilepsy (DRE) treated with cenobamate experience meaningful reductions in seizure frequency and high rates of treatment retention, according to the findings of a study published in Epilepsia Open. Individuals with DRE face limited options after multiple antiseizure medications (ASMs) fail to provide seizure control.
FDA Approves Rinvoq for Giant Cell Arteritis

1 week ago | clinicaladvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA). The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial (ClinicalTrials.gov Identifier: NCT03725202), which evaluated the safety and efficacy of upadacitinib in participants aged 50 years and older with new-onset or relapsing GCA.
Atzumi Nasal Powder Approved for Acute Treatment of Migraine

1 week ago | clinicaladvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has approved Atzumi™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi is a drug-device combination consisting of dihydroergotamine (DHE), an ergotamine derivative.
Oral Semaglutide 25 mg Under Review for Chronic Weight Management

1 week ago | clinicaladvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a 25 mg oral formulation of semaglutide for chronic weight management in adults with obesity or overweight, with 1 or more comorbid conditions, and to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
GLP-1RA Plus Thiazolidinedione Reduces All-Cause, CV Mortality Risk in T2D

1 week ago | clinicaladvisor.com | Jessica Nye

The combination of a glucagon-like peptide 1 receptor agonist (GLP-1RA) and thiazolidinedione results in lower all-cause and cardiovascular (CV) mortality rates than nonuse among patients with type 2 diabetes (T2D). These findings were published in JAMA Network Open. There is a paucity of data about outcomes from the combination of GLP-1RAs and thiazolidinedione.
Metabolic Syndrome Tied to Sleep Apnea Symptoms in Young Adults

2 weeks ago | clinicaladvisor.com | Lisa M Kuhns

Metabolic syndrome parameters are significantly associated with sleep apnea symptoms among US adolescents and young adults (AYAs) with notable disparities across racial and ethnic groups, according to study results published in Obesity Science and Practice.
Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available

2 weeks ago | clinicaladvisor.com | Diana Ernst

An additional vial size of Tepylute®, a ready-to-dilute formulation of thiotepa, has been approved by the Food and Drug Administration. Tepylute is indicated for the treatment of adenocarcinoma of the breast or ovary. It is now supplied as a multiple-dose vial containing 100mg of thiotepa, in addition to the previously approved single-dose vial containing 15mg of the alkylating drug. This formulation of thiotepa eliminates the need for reconstitution.